Copyright © 1992, American Society for Microbiology In Vitro Activity of L-627, a New Carbapenem

The in vitro activity of L-627, a new parenterally administered carbapenem, was compared with those of imipenem, meropenem, FCE 22101 (a penem), ceftazidime, and ceftriaxone. L-627 was active against members of the family Enterobacteriaceae (MIC for 90%o of strains tested [MIC90] ranging from 0.03 to 4,ug/ml). L-627 displayed activity equal to that of meropenem against Pseudomonas aeruginosa (MIC90, 2,ug/ml), although, as with other carbapenems, the antipseudomonal activity was reduced against D2-deficient strains. Staphylococci and streptococci were susceptible (MIC90 of 1.0 jiLg/ml for Staphylococcus aureus and 0.015,ug/ml for group A streptococci). L-627 also had activity against anaerobic bacteria (MIC90, 2.0,ug/ml for Bacteroidesfragilis). Neisseria gonorrhoeae and Neisseria meningitidis were highly susceptible (MIC90, 0.06,ug/ml), and against the common respiratory pathogens (Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrha-lis), the MIC90s were <2.0,ug/ml. The protein binding of L-627 ranged from 13.8 to 22%, depending on the concentration. The presence of human serum had little effect on the MIC or MBC of L-627. These results suggest that L-627 merits further study in the treatment of infections caused by a wide range of pathogens. L-627 (LJC 10,627) {(1R,5S,6S)-2-[(6,7-dihydro-5H-pyra-zolol[1,2-oa][1,2,4,]triazolium-6-yl)]thio-6-[(R)-1-hydroxy-ethyl]-1-methyl-carbapenem-3-carboxylate} is a new inject